RxDoctor Payments Data

Chad Mongrain, DO

Family Medicine · Davenport, WANPI 1720028244

Payments from drug & device makers

$836in general payments, 2019–2025

Across 58 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$183
  • Amgen$183
  • Pfizer$147
  • AstraZeneca$107
  • Johnson & Johnson$53
  • Astellas Pharma US Inc$31
  • plus $131 from 8 others

What the payments were for

  • Food & beverage$836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$836 in reported general payments places this provider in the 80th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$4,206
Medicare patients
34
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban75$82,393
JardianceEmpagliflozin48$49,216
FarxigaDapagliflozin Propanediol27$31,888
EliquisApixaban37$27,172
TrulicityDulaglutide19$24,065
OzempicSemaglutide17$16,945
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$9,117
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$8,557
Advair HfaFluticasone Propion/Salmeterol26$8,136
EntrestoSacubitril/Valsartan12$7,957
Potassium Chloride99$3,154
Gabapentin122$3,090
Duloxetine Hcl64$2,943
Atorvastatin Calcium273$2,585
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$2,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$53$82,39375 claims
Boehringer IngelheimJardiance$14$49,21648 claims
AstraZenecaFarxiga$107$31,88827 claims
PfizerEliquis$147$27,17237 claims
Lilly USA, LLCTrulicity$25$24,06519 claims
Novo NordiskOzempic$183$16,94517 claims
Sanofi-aventis U.S. LLCLantus$13$2,25617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Davenport

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →